Oculis Holding (NasdaqGM:OCS) has hit several key clinical milestones, including FDA Special Protocol Assessment agreement for its PIONEER-1 Phase 3 trial of Privosegtor in optic neuritis and completion of critical DIAMOND Phase 3 visits for OCS-01.

Oculis Holding’s recent FDA SPA agreement for PIONEER-1 and progress in its DIAMOND Phase 3 program have come alongside a 56.85% year to date share price return and an 81.54% 1 year total shareholder return. This suggests momentum has been building over both shorter and longer periods.

If you like the mix of clinical progress and strong recent returns here, it may be worth scanning for other healthcare stocks using advanced AI, starting with 33 healthcare AI stocks

With Oculis Holding posting strong recent returns, a discounted share price relative to analyst targets and an early stage revenue base, the key question is whether the stock still sits at a discount or if markets already price in future growth.

Price-to-Book of 7.4x: Is it justified?

On a P/B basis, Oculis Holding trades at 7.4x book value, which is materially richer than both its US pharmaceuticals peers and the wider industry.

The P/B ratio compares the company’s market value to its net assets on the balance sheet. It is often used for early stage or unprofitable biopharma stocks where earnings are still negative. A higher P/B can reflect investor willingness to pay up for future pipeline potential and forecast revenue growth rather than current profitability.

Here, the stock is described as expensive versus both its direct peers and the broader US pharmaceuticals industry. That suggests the market is already assigning a premium to Oculis Holding’s clinical portfolio and growth forecasts, even though the business currently reports a loss of $94.596 million and only $1.123 million of revenue.

Compared to a US pharmaceuticals industry average P/B of 2.6x and a peer group average of 3.8x, the 7.4x multiple stands out as materially higher. For anyone weighing up the recent share price strength and analyst optimism against valuation, this gap is an important reference point.

Result: Price-to-book of 7.4x (OVERVALUED)

However, there are clear risks here, including Oculis Holding’s US$94.596 million loss and early stage US$1.123 million revenue, which leave little cushion if trials disappoint.

Another View: DCF Points the Other Way

While the 7.4x P/B ratio presents Oculis Holding as expensive versus peers, our DCF model provides a different perspective. At a share price of $31.37, the stock is described as trading around 83% below an estimated future cash flow value of $185.05, which indicates a very large implied upside.

That kind of gap can either highlight a significant opportunity or suggest that the cash flow assumptions are very optimistic, so it comes down to which set of expectations you consider more realistic.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Oculis Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such a wide spread between valuation signals, sentiment on Oculis Holding is clearly mixed. Act quickly, review the numbers yourself and weigh up the 3 key rewards and 3 important warning signs

Looking for more investment ideas?

If Oculis Holding has caught your attention, do not stop there. Broaden your watchlist with other opportunities that fit different strengths and risk profiles.

• Pinpoint potential bargains by scanning 46 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect their underlying strength.
• Strengthen your income focus by reviewing 14 dividend fortresses that combine higher yields with the potential for more consistent cash distributions.
• Protect your downside by zeroing in on 68 resilient stocks with low risk scores that score well on resilience and balance sheet strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.